J&J Pulls Zeftera From Canada Amid Trial Conduct Questions

Janssen-Ortho, a Johnson & Johnson (J&J) company, is halting Canadian sales of Zeftera, its skin-infection treatment, after the FDA and the EU expressed concerns about the sponsor’s conduct of clinical trials. The drugmaker planned to stop selling Zeftera (ceftobiprole) last week, Basilea Pharmaceutica, which licensed the drug to J&J, said. Discussions with Health Canada stemmed from negative U.S. and EU regulatory recommendations about ceftobiprole.
Clinical Trials Advisor